Pharmac and Prime Minister Jacinda Ardern announced the agreement this morning. Pharmac said the oral antiviral drug would be used to treat New Zealanders with mild to moderate Covid-19 symptoms.
The agreement with supplier Merck Sharp & Dohme (MSD) is subject to the drug being approved by Medsafe. An initial supply of 60,000 courses will be sent to New Zealand after Medsafe approves the drug, Pharmac chief executive Sarah Fitt said in a statement.
“MSD recently announced trial results showing that molnupiravir considerably reduced hospitalisations and deaths from Covid-19. While these are interim results, they are very promising,” Fitt said.